Medicago, based in Quebec City, describes itself as "a pioneer of plant-based transient expression and manufacturing." Earlier this month, the company said its adjuvanted vaccine candidatein Phase 1 of testing.
Of the aforementioned antibody response, Ward cautioned that that's not the same as what other companies, like Pfizer, have previously announced. Ward admits the company is "a couple of months behind" global competitors but he suggests the Medicago vaccine candidate could be ready by summer 2021 and that the company could produce as many as a million doses per month in Canada and even more in the U.S.
In October, the company announced that they had reached an agreement with the federal government to supply Canada with up to 76 million doses of their vaccine, subject to approval from Health Canada.